The assays have been developed by Nuvera and the University of Texas MD Anderson Cancer Center. The Nuvera test portfolio will also be capable of reporting status of standard tumor markers such as ER and Her2, said Nuvera.
As part of the licensing agreement, Nuvera will receive an upfront payment and will earn payments for performance milestones over the next several years from Veridex as the products move through commercialization and revenue-based milestones.
Nuvera said that it will continue to support test validation by using its expertise in diagnostics and bioinformatics, and by leveraging its partnership with MD Anderson and other leading cancer centers. Veridex will complete clinical studies and market development for the test, and commercialize the test through its marketing and sales operations. Nuvera will also receive royalty payments for product sales generated by Veridex worldwide.
Nandan Padukone, president and CEO of Nuvera, said: “We believe the uniqueness of our tests is not just their therapy-directed focus but that they can potentially be combined with Veridex tests into a single test platform that could enable important, effective decisions from a single tumor sample.”